Philips: Automated 3D Echocardiographic analysis of left-heart chambers is an accurate alternative to conventional manual methodology

Philips HeartModelA.I. provides clear, quick automated measurements to help clinicians confidently assess patients.

AMSTERDAM, 03-May-2017 — /EuropaWire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the results from a global study indicating that automated three-dimensional echocardiographic (3DE) analysis of left-heart chambers is an accurate alternative to conventional manual methodology. This multicenter study assessed Philips HeartModel^A.I. Anatomically Intelligent Ultrasound (AIUS) software and builds on the conclusions of the previous clinical assessments carried out at individual locations by affirming consistency and reproducibility across multiple laboratories. 

Published in European Heart Journal, the study aimed to determine the accuracy and reproducibility of three different heart measurements in a multicenter setting: left atrial (LA) volume, left ventricular (LV) volume and ejection fraction (EF). Researchers imaged 180 patients across six sites using 3DE with the Philips EPIQ ultrasound system. All images were analyzed using automated Philips HeartModel^A.I. software, which brings advanced quantification, automated 3D views and robust reproducibility to cardiac ultrasound imaging.  

“The days of time-consuming, difficult collection and analysis of heart measurements are behind us,” said Dr. Roberto Lang, professor of medicine and director of noninvasive cardiac imaging laboratories, University of Chicago Medicine. “The results of this study provide further evidence that 3DE technology like Philips HeartModelA.I. is the way forward for global health systems to save time and gather accurate data for quality care delivery to patients.”  

Current medical guidelines recommend 3DE chamber quantification for patients undergoing an echocardiography exam, but adoption in clinical practice has lagged due to time-consuming analysis that has traditionally been associated with the process. By showing that experienced readers in different parts of the world can obtain accurate and reproducible automated measurements of LVEDV, LVESV and LVEF with clinically non-significant differences, this research demonstrates that HeartModel A.I. is a time saving option that yields consistent, reproducible results across laboratories.  

These findings could contribute to fuller integration of 3DE quantification into clinical routine. Automated 3DE provides a comprehensive picture of heart function with real-time results, which can help clinicians assess and diagnose patients quickly and confidently.  

“It’s exciting to see the impact of the Philips EPIQ system and HeartModelA.I. software at work around the world,” stated Dr. Alexandra Gonçalves, senior medical director, Cardiovascular Ultrasound, Philips. “With these tools, Philips is empowering clinicians with diagnostic confidence and facilitating wider adoption of innovative technology for cardiac imaging.” 

Philips HeartModel^A.I. is designed to allow clinicians and researchers to quickly, easily and confidently assess disease states and determine treatment. Anatomical Intelligence is used in Philips imaging solutions such as EPIQ, Affiniti, and EchoNavigator. To learn more about AIUS and the full suite of Philips innovative ultrasound solutions, please visit http://www.philips.com/ultrasound or follow @PhilipsHealth. 

For further information, please contact:

Alicia Cafardi
Philips Group Press Office
Mobile: +1 412 523 9616
Email: Alicia.Cafardi@philips.com  <

Twitter: @aliciacafardi

Sarah Haeger
Philips Ultrasound
Mobile: +1 206-920-8726
Email: Sarah.Haeger@philips.com
Twitter: @sarahhaeger

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. 

SOURCE: Koninklijke Philips N.V.